On September 28, 2023, the Board of Directors of ADMA Biologics, Inc. appointed Alison C. Finger to serve on the Board as a Class I director with a term expiring at the Company?s 2026 annual meeting of stockholders. Ms. Finger served as Chief Commercial Officer at bluebird bio, Inc., a biotechnology company, or bluebird, from August 2015 to January 2021. Prior to bluebird, Ms. Finger served at Bristol-Myers Squibb Company, a pharmaceutical company, or BMS, in roles with increasing responsibility, including as Vice President, Global Commercialization Virology from July 2004 to June 2007, Managing Director, Australia & New Zealand from July 2007 to May 2009, VP Global Commercialization, Alzheimer?s/Neuroscience from May 2009 to December 2012 and VP Global Commercialization, Hematology from December 2012 to May 2014.

Ms. Finger previously served as a member of the board of directors of Decibel Therapeutics, a biotechnology company, from December 2021 until the acquisition of Decibel Therapeutics in September 2023 and as a member of the board of directors of VBL Therapeutics, a biotechnology company from July 2021 to August 2022. Ms. Finger has a B.A. from St. Lawrence University and an M.B.A. from the Fuqua School of Business at Duke University.